2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 million
Novo Nordisk has purchased 2seventy bio’s Hemophilia A program, along with rights to some of the biotech’s gene editing tech for autoimmune diseases, in a deal worth up to $40 million. nnAs part of the divestiture, the 2seventy staff members currently involved with the program will also head over to Novo to work on the science, according to a company release shared June 26 after market close.
EU regulator requires secondary cancer risk warning for CAR-T therapies
2seventy bio to Participate in Upcoming Investor Conferences
Phil Gregory’s new gig looks a whole lot like his old gig. It’s just that, under the umbrella of Regeneron, things have gotten a bit bigger.
2seventy bio Reports First Quarter Financial Results and Recent Operational Progress
2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024
US FDA mandates label updates on CAR-T cancer therapies
After a short period of doubt, the FDA has followed the opinion of its advisers and moved Bristol Myers Squibb’s CAR-T therapy Abecma into the earlier treatment of multiple myeloma.
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy